CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

ustekinumab

Last Updated: August 12, 2016
Result type: Reports
Project Number: SR0501-000
Product Line: Reimbursement Review

Generic Name: ustekinumab

Brand Name: Stelara/Stelara I.V.

Manufacturer: Janssen Inc.

Indications: Crohn’s disease

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: March 21, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions